Cepheid

Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.

The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.

The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The test for resistance genes from carbapenemase-producing Gram-negative bacteria can now be used on perirectal swabs and pure colonies.

The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The new instrument has higher throughput than competing systems, while the flu test boasts enhanced sensitivity and protection against seasonal drift.

The Xpert Xpress Flu can detect both influenza A and B virus in 20 minutes from either nasopharyngeal or nasal swabs.

Pages

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.